1. Home
  2. EOLS

as of 07-17-2026 3:55pm EST

$5.71
+$0.08
+1.33%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.

Founded: 2012 Country:
United States
United States
Employees: N/A City: NEWPORT BEACH
Market Cap: 454.4M IPO Year: 2018
Target Price: $15.50 AVG Volume (30 days): 776.9K
Analyst Decision: Strong Buy Number of Analysts: 5
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.16 EPS Growth: 1.23
52 Week Low/High: $3.86 - $10.20 Next Earning Date: 05-04-2026
Revenue: $297,176,000 Revenue Growth: 11.61%
Revenue Growth (this year): 13.27% Revenue Growth (next year): 17.62%
P/E Ratio: -35.28 Index: N/A
Free Cash Flow: -45706000.0 FCF Growth: N/A

AI-Powered EOLS Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 2 days ago

AI Recommendation

hold
Model Accuracy: 73.89%
73.89%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Earnings Transcripts

SEC 8-K filings with transcript text

View All
2026
Q1

Q1 2026 Earnings

8-K BUY

May 4, 2026 · 100% conf.

AI Prediction BUY

1D

+13.16%

$6.31

5D

+10.76%

$6.18

20D

+8.00%

$6.03

Price: $5.58 Prob +5D: 100% AUC: 1.000
0001570562-26-000064

SEC.gov | Request Rate Threshold Exceeded

U.S. Securities and Exchange Commission

You’ve Exceeded the SEC’s Traffic Limit

Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.

Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.

The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.

For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.

For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.

Reference ID: 0.c706d217.1784376398.d54eafb8

More Information

Internet Security Policy

By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.

Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).

To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.

If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.

Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.

Note: We do not offer technical support for developing or debugging scripted downloading processes.

2025
Q4

Q4 2025 Earnings

8-K SELL

Mar 3, 2026 · 100% conf.

AI Prediction SELL

1D

-7.03%

$5.27

Act: +1.85%

5D

-10.69%

$5.06

Act: -8.33%

20D

-8.67%

$5.17

Price: $5.67 Prob +5D: 0% AUC: 1.000
0001628280-26-013872

eols-202603030001570562false00015705622026-03-032026-03-03

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 3, 2026

EVOLUS, INC.

(Exact name of registrant as specified in its charter)

Delaware 001-38381 46-1385614

(State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)

520 Newport Center Drive, Suite 1200 Newport Beach, California 92660 (Address of principal executive offices) (Zip Code)

(949) 284-4555 (Registrant’s telephone number, including area code) N/A (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of ClassTrading Symbol(s)Name of each exchange on which registered Common Stock, par value $0.00001 per shareEOLSThe Nasdaq Stock Market LLC (Nasdaq Global Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01     Entry into a Material Definitive Agreement.

On March 3, 2026, Evolus, Inc. (the “Company”) entered into a Loan and Security Agreement (the “Loan Agreement”) with Eclipse Business Capital LLC, as administrative agent (the “Agent”) and the lenders party thereto.

The Loan Agreement provides for a senior secured asset-based revolving credit facility of up to $30.0 million (the “Revolving Credit Facility”), subject to a borrowing base formula based on eligible accounts receivable and eligible inventory, in each case reduced by customary reserves. The Revolving Credit Facility includes an uncommitted accordion feature of up to $10.0 million, exercisable subject to lender consent and other conditions. The Revolving Credit Facility is subject to a minimum utilization requirement of $10.0 million and matures on March 3, 2029.

Borrowings under the Revolving Credit Facility bear interest at a rate equal to adjusted term secured overnight financing rate (“SOFR”) (subject to a floor of 2.0%) plus an applicable margin of 4.25%, which is subject to downward adjustments based on certain coverage ratio and excess availability. The Revolving Facility and the Accordion Facility are subject to a closing fee equal to 1.0% and prepayment fees equal to 3.0% during the first year, 2.0% during the second year, and zero percent thereafter, subject to certain exceptions.

All obligations of the Company under the Loan Agreement are secured by substantially all of the assets of the Company, subject to customary exceptions.

The Loan Agreement requires the Company to maintain minimum excess availability at all times and limits capital expenditures. The Loan Agreement contains customary representations and warranties, affirmative and negative covenants and events of default, including cross-defaults to other material indebtedness, bankruptcy and insolvency-related events and a change of control. Upon the occurrence and continuation of an event of default, the Agent may terminate the commitments, accelerate all outstanding obligations and exercise remedies with respect to the collateral.

The foregoing description of the Loan Agreement is not complete and is qualified in its entirety by reference to the full text of such agreement, a copy of which is attached as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 2.02    Results of Operations and Financial Condition.

On March 3, 2026, the Company issued a press release announcing its financial results for the quarter and year ended December 31, 2025. The press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. As provided in General Instruction B.2 of Form 8-K, the information in this Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchan

2025
Q4

Q4 2025 Earnings

8-K SELL

Jan 9, 2026 · 100% conf.

AI Prediction SELL

1D

-7.03%

$5.27

Act: +1.85%

5D

-10.69%

$5.06

Act: -8.33%

20D

-8.67%

$5.17

Price: $5.67 Prob +5D: 0% AUC: 1.000
0001570562-26-000003

eols-202601090001570562false00015705622026-01-092026-01-09

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 9, 2026

EVOLUS, INC.

(Exact name of registrant as specified in its charter)

Delaware 001-38381 46-1385614

(State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)

520 Newport Center Drive, Suite 1200 Newport Beach, California 92660 (Address of principal executive offices) (Zip Code)

(949) 284-4555 (Registrant’s telephone number, including area code) N/A (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of ClassTrading Symbol(s)Name of each exchange on which registered Common Stock, par value $0.00001 per shareEOLSThe Nasdaq Stock Market LLC (Nasdaq Global Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02    Results of Operations and Financial Condition.

On January 9, 2026, Evolus, Inc. (the "Company") issued a press release announcing its preliminary, unaudited net revenue and certain other operational and financial data for the quarter and year ended December 31, 2025. The press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. As provided in General Instruction B.2 of Form 8-K, the information in this Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01    Financial Statements and Exhibits.

(d)    Exhibits.

Exhibit Number Description

99.1Press Release of Evolus, Inc., dated January 9, 2026

104Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Evolus, Inc.

Dated: January 9, 2026/s/ David Moatazedi

David Moatazedi

President and Chief Executive Officer

Share on Social Networks: